News Column

DGAP-News: Proteros announces a USD 12 million Series A Financing of Rodin Therapeutics, a Company founded by Atlas Venture and Proteros, Focussing on Novel Treatments for CNS Disorders

May 29, 2014

DGAP-News: Proteros biostructures GmbH / Key word(s): Investment Proteros announces a USD 12 million Series A Financing of Rodin Therapeutics, a Company founded by Atlas Venture and Proteros, Focussing on Novel Treatments for CNS Disorders 29.05.2014 / 13:29 --------------------------------------------------------------------- Proteros announces a USD 12 million Series A Financing of Rodin Therapeutics, a Company founded by Atlas Venture and Proteros, Focussing on Novel Treatments for CNS Disorders MUNICH, Germany / Cambridge, MA, USA - 29 May 2014 - Proteros biostructures GmbH, a German biotech company specialized in protein-structure accelerated lead discovery, announced today the completion of a Series A financing round of Rodin Therapeutics, Inc, located in Boston, MA. Rodin Therapeutics, founded by Atlas Venture and Proteros, is a capital efficient approach with the mission to apply insights in epigenetics to novel therapeutics for neurological disorders. Current investors Atlas Venture and Johnson and Johnson Innovation Center led the financing round. Rodin will use the proceeds in the amount of USD 12 million to advance its pipeline of selective epigenetic modulators towards the clinic. Since its inception in March 2013, Rodin has advanced its internal pipeline of epigenetic modulators and an additional chemical series, obtained under an exclusive license from the Broad Institute. The Rodin approach is a combination of high potential biology, unique chemistry, a strong team and Proteros' key capabilities in structure accelerated lead discovery, which enable an orthogonal evaluation of the interactions of small molecules and epigenetic targets. The Rodin team comprises senior executives of Atlas, Johnson and Johnson Innovation Center and Proteros. The company has also assembled an esteemed Scientific Advisory Board of leaders in the field of neurology and epigenetics. Torsten Neuefeind, Chief Executive Officer of Proteros commented: "Rodin is the first proprietary lead discovery project initiated by Proteros that we successfully transferred into a joint venture with industry-renowned partners and that now closed its second financing round. This is an important step for Rodin and a capital efficient business model for all stakeholders." About Proteros biostructures Proteros biostructures, located in Martinsried/Munich, is a privately-held company, focussing on protein-structure accelerated lead discovery. Proteros has established a unique and powerful platform for the integration of protein crystallography, biophysics - particularly kinetic and thermodynamic profiling-, tailor-made protein production for biophysical applications, and Medicinal Chemistry. In addition to its service business, Proteros has built a growing proprietary pipeline of lead discovery projects, focusing on the most challenging and innovative targets that are highly amenable to its technologies. Proteros is market leader in structural biology and collaborates with more than 80 pharmaceutical and biotechnology clients in North America, Europe and Asia. For more information, visit www.proteros.de About Rodin Therapeutics Rodin Therapeutics is discovering and developing first in class therapeutics for cognitive disorders, applying unique insights into the role of epigenetics and best in class structural biology capabilities. Applying Rodin's unique access to the Proteros structural biology platform and deep experience in CNS drug development, the company has identified high potential targets and novel chemical strategies to address high unmet clinical needs. Rodin was co-founded by Atlas Venture and Proteros Biostructures, with financing from the Johnson & Johnson Development Corporation (JJDC) Seed Fund. For more information, visit rodintherapeutics.com About Atlas Venture Atlas Venture is a leading early-stage international venture capital firm that invests in technology and life sciences businesses. Since inception in 1980, its partners have helped build over 350 companies in more than 16 different countries. Atlas Venture is currently investing from its ninth fund which closed in May 2013. For more information, visit www.atlasventure.com. Contacts: Dr. Torsten Neuefeind, CEO Proteros biostructures GmbH Email: neuefeind[at]proteros.de For Press enquiries: Katja Arnold, MC Services AG Email: katja.arnold[at]mc-services.eu Phone: +49 160 93603022 End of Corporate News --------------------------------------------------------------------- 29.05.2014 Dissemination of a Corporate News, transmitted by DGAP - a company of EQS Group AG. The issuer is solely responsible for the content of this announcement. DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de --------------------------------------------------------------------- 271202 29.05.2014


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: DGAP Corporate News


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters